Jiangsu Hualan New Pharmaceutical Material Co. Ltd.
Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. engages in the research and development, manufacture, and sale of packaging materials for the pharmaceuticals' industry in China and internationally. It offers covered rubber stoppers serise; halogenated butyl rubber stopper freeze-dryied series; halogenated butyl rubber stopper antibiotics series; halogenated butyl rubber plugs infusion series;… Read more
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) - Total Liabilities
Latest total liabilities as of June 2025: CN¥256.27 Million CNY
Based on the latest financial reports, Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (301093) has total liabilities worth CN¥256.27 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DEME Group NV
BR:DEME
|
Belgium | €3.78 Billion |
|
SKC Co. Ltd
KO:011790
|
Korea | ₩4.56 Trillion |
|
Narayana Hrudayalaya Ltd.
NSE:NH
|
India | ₹36.80 Billion |
|
Primaris Real Estate Investment Trust
PINK:PMREF
|
USA | $2.75 Billion |
|
YGSOFT Inc
SHE:002063
|
China | CN¥654.07 Million |
|
Stadler Rail AG
PINK:SRAIF
|
USA | $4.81 Billion |
|
Gemalto N.V
OTCGREY:GTOFF
|
USA | $13.12 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Hualan New Pharmaceutical Material Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Hualan New Pharmaceutical Material Co. Ltd. (2019–2024)
The table below shows the annual total liabilities of Jiangsu Hualan New Pharmaceutical Material Co. Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥255.99 Million | +13.57% |
| 2023-12-31 | CN¥225.40 Million | +37.26% |
| 2022-12-31 | CN¥164.21 Million | -24.16% |
| 2021-12-31 | CN¥216.51 Million | -3.87% |
| 2020-12-31 | CN¥225.23 Million | -4.97% |
| 2019-12-31 | CN¥237.02 Million | -- |